{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:58:07Z","timestamp":1788721087328,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Macrolide-resistant Mycoplasma pneumoniae (MRMP) strains are increasingly prevalent, leading to a rise in severe Mycoplasma pneumoniae pneumonia incidence annually, which poses a significant threat to children\u2019s health. This study aimed to compare the effectiveness and safety of oral minocycline and doxycycline for the treatment of severe MRMP pneumonia in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective analysis included children treated for severe MRMP pneumonia at the Pediatric Department of Tongji Hospital, Shanghai, China, between September 2023 and January 2024 using minocycline and doxycycline. The patients were divided into four groups according to treatment: oral doxycycline alone (DOX group), oral minocycline alone (MIN group), oral doxycycline with intravenous glucocorticoids (DOXG group), and oral minocycline with intravenous glucocorticoids (MING group). Student\u2019s <jats:italic>t-<\/jats:italic>test, Mann\u2013Whitney U test, and <jats:italic>\u03c7<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> or <jats:italic>Fisher\u2019s<\/jats:italic> exact tests were used for group comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 165 patients were included in this study: 84 received minocycline, and 81 received doxycycline. The DOX group had higher fever resolution rates within 24, 48, and 72\u00a0h compared to the MIN group (63.2% vs. 31.8%, 79.0% vs. 63.6%, and 100% vs. 90.9%, respectively; all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The DOXG group showed higher fever resolution rates within 24 and 48\u00a0h than the MING group (92.3% vs. 83.4%, 100% vs. 92.7%, all <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). There were no statistically significant differences in time to imaging improvement, cough improvement, and disappearance of wet rales between groups, regardless of glucocorticoid combination. The longer the duration of fever prior to tetracycline therapy, the greater the likelihood of hypoxemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.039) and a greater than two-fold elevation in the D-dimer level (<jats:italic>p<\/jats:italic>\u2009=\u20090.004).Univariate binary logistic regression model analysis revealed that CRP and erythrocyte sedimentation rate at disease onset were associated with defervescence within 24\u00a0h after treatment with tetracyclines alone (<jats:italic>p<\/jats:italic>\u2009=\u20090.020, <jats:italic>p<\/jats:italic>\u2009=\u20090.027), with erythrocyte sedimentation rate also influencing defervescence within 48\u00a0h (<jats:italic>p<\/jats:italic>\u2009=\u20090.022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Doxycycline treatment resulted in a higher rate of defervescence than minocycline. Prompt treatment reduced the probability of pleural effusion, hypoxemia, pulmonary atelectasis, and D-dimer levels\u2009&gt;\u20092 times the reference value.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-10070-3","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T03:41:40Z","timestamp":1729050100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a retrospective analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaoxiao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"10070_CR1","doi-asserted-by":"crossref","unstructured":"Lv Y T, Sun X J, Chen Y, et al. Epidemic characteristics of Mycoplasma pneumoniae infection: a retrospective analysis of a single center in Suzhou from 2014 to 2020 [J]. Annals Translational Med. 2022;10(20):1123.","DOI":"10.21037\/atm-22-4304"},{"key":"10070_CR2","doi-asserted-by":"crossref","unstructured":"Gao L W Yinj, Hu Y H, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016 [J]. Epidemiol Infect. 2019;147:e192.","DOI":"10.1017\/S0950268819000839"},{"key":"10070_CR3","doi-asserted-by":"crossref","unstructured":"Tong L, Huang S, Zheng C et al. Refractory Mycoplasma pneumoniae Pneumonia in Children: early recognition and management [J]. J Clin Med, 2022, 11(10).","DOI":"10.3390\/jcm11102824"},{"key":"10070_CR4","doi-asserted-by":"crossref","unstructured":"Yan, C, Xue G H, Zhao H Q, et al. Current status of Mycoplasma pneumoniae infection in China [J]. World J Pediatrics: WJP. 2024;20(1):1\u20134.","DOI":"10.1007\/s12519-023-00783-x"},{"key":"10070_CR5","doi-asserted-by":"crossref","unstructured":"Gong C, Huang F. Suo L, Increase of respiratory illnesses among children in Beijing, China, during the autumn and winter of 2023 [J]. Euro surveillance: bulletin Europeen sur les maladies transmissibles\u2009=\u2009European communicable disease bulletin, 2024, 29(2).","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300704"},{"key":"10070_CR6","unstructured":"Prc, N H C O. T. diagnosis and treatment guidelines for mycoplasma pneumoniae pneumonia in children(2023 Edition) [J]. Infect Disease Inform. 2023;36(4):291\u20137."},{"key":"10070_CR7","doi-asserted-by":"crossref","unstructured":"Zhou Y, Shan Y, Cui Y, et al. Characteristics and outcome of severe Mycoplasma pneumoniae Pneumonia admitted to PICU in Shanghai: a retrospective cohort study [J]. Crit care Explorations. 2021;3(3):e0366.","DOI":"10.1097\/CCE.0000000000000366"},{"key":"10070_CR8","doi-asserted-by":"crossref","unstructured":"Chen J, Qi X, Yin Y, et al. Effects of minocycline on macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study [J]. Translational Pediatr. 2021;10(11):2997\u20133004.","DOI":"10.21037\/tp-21-356"},{"key":"10070_CR9","unstructured":"Medicine, N H C O T P S R O C S A O T. C. Guideline for diagnosis and treatment of community acquired pneumonia in Chilren(2019 version) [J]. Chin J Clin Infect Dis. 2019;12(1):6\u201313."},{"key":"10070_CR10","unstructured":"Child Allergy Professional Committee C A F P O H S A, Capital T G Z M F C S H A T, Institute of pediatrics union; Otolaryngology group S O P, chinese medical doctor. Expert consensus on diagnosis and treatment of COVID\u201319 infection related cough in children [J]. Chin J Prev Med. 2023;57(3):309\u201317."},{"key":"10070_CR11","doi-asserted-by":"crossref","unstructured":"Waites K B Xiaol, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond [J]. Clin Microbiol Rev. 2017;30(3):747\u2013809.","DOI":"10.1128\/CMR.00114-16"},{"key":"10070_CR12","doi-asserted-by":"crossref","unstructured":"Saraya T. The history of Mycoplasma pneumoniae pneumonia [J]. Front Microbiol. 2016;7:364.","DOI":"10.3389\/fmicb.2016.00364"},{"key":"10070_CR13","doi-asserted-by":"crossref","unstructured":"Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan [J]. Antimicrob Agents Chemother. 2004;48(12):4624\u201330.","DOI":"10.1128\/AAC.48.12.4624-4630.2004"},{"key":"10070_CR14","doi-asserted-by":"crossref","unstructured":"Jiang T T Sunl, Wang T Y, et al. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic [J]. Front Cell Infect Microbiol. 2023;13:1181402.","DOI":"10.3389\/fcimb.2023.1181402"},{"key":"10070_CR15","unstructured":"Wang Ys, Zhou Y L, Bai G N, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children [J]. World journal of pediatrics: WJP,; 2024."},{"issue":"13","key":"10070_CR16","doi-asserted-by":"publisher","first-page":"e33697","DOI":"10.1016\/j.heliyon.2024.e33697","volume":"10","author":"M Leng","year":"2024","unstructured":"Leng M, Yang J, Liu X. Macrolide-resistant mycoplasma pneumoniae infection in children observed during a period of high incidence in Henan. China [J] Heliyon. 2024;10(13):e33697.","journal-title":"China [J] Heliyon"},{"issue":"7","key":"10070_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ppul.24327","volume":"54","author":"C Yan","year":"2019","unstructured":"Yan C, Xue G, Zhao H, et al. Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children [J]. Pediatr Pulmonol. 2019;54(7):1012\u201321.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10070_CR18","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1038\/s41598-024-58784-3","volume":"14","author":"X Zhang","year":"2024","unstructured":"Zhang X, Sun R, Jia W, et al. A new dynamic nomogram for predicting the risk of severe Mycoplasma pneumoniae pneumonia in children [J]. Sci Rep. 2024;14(1):8260.","journal-title":"Sci Rep"},{"issue":"2","key":"10070_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","volume":"17","author":"Y Kawai","year":"2012","unstructured":"Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients [J]. Respirol (Carlton Vic). 2012;17(2):354\u201362.","journal-title":"Respirol (Carlton Vic)"},{"issue":"12","key":"10070_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/cid\/cis784","volume":"55","author":"T Okada","year":"2012","unstructured":"Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children [J]. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2012;55(12):1642\u20139.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"3","key":"10070_CR21","doi-asserted-by":"publisher","first-page":"e0173635","DOI":"10.1371\/journal.pone.0173635","volume":"12","author":"N Ishiguro","year":"2017","unstructured":"Ishiguro N, Koseki N, Kaiho M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients [J]. Plos One. 2017;12(3):e0173635.","journal-title":"Plos One"},{"issue":"10","key":"10070_CR22","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1128\/AAC.00737-13","volume":"57","author":"N Miyashita","year":"2013","unstructured":"Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy [J]. Antimicrob Agents Chemother. 2013;57(10):5181\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"10070_CR23","doi-asserted-by":"crossref","unstructured":"Lee H, Choi Y Y, Sohn Y J, et al. Clinical Efficacy of Doxycycline for Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children [J]. Antibiotics (Basel, Switzerland), 2021, 10(2).","DOI":"10.3390\/antibiotics10020192"},{"key":"10070_CR24","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhang Y, Tang Q N, et al. Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods [J]. Ital J Pediatr. 2024;50(1):38.","DOI":"10.1186\/s13052-024-01615-y"},{"key":"10070_CR25","doi-asserted-by":"crossref","unstructured":"Chen Y C, Hsu W Y, Chang T H. Macrolide-resistant Mycoplasma pneumoniae infections in Pediatric Community-Acquired pneumonia [J]. Emerg Infect Dis. 2020;26(7):1382\u201391.","DOI":"10.3201\/eid2607.200017"},{"key":"10070_CR26","doi-asserted-by":"crossref","unstructured":"Cao B, Zhao C J, Yin Y D, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China [J]. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2010;51(2):189\u201394.","DOI":"10.1086\/653535"},{"key":"10070_CR27","doi-asserted-by":"crossref","unstructured":"Tsai T A, Tsai C K, Kuo K C, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children [J]. Journal of microbiology, immunology, and infection\u2009=\u2009Wei Mian Yu Gan ran Za Zhi, 2021, 54(4): 557\u201365.","DOI":"10.1016\/j.jmii.2020.10.002"},{"key":"10070_CR28","doi-asserted-by":"crossref","unstructured":"Lung D C, Yip E K, Lam D S, et al. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children [J]. Pediatr Infect Dis J. 2013;32(12):1396\u20139.","DOI":"10.1097\/INF.0b013e3182a25c71"},{"key":"10070_CR29","doi-asserted-by":"crossref","unstructured":"Li P, Wang W, Zhang X, et al. Observational retrospective clinical study on clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese pediatric cases [J]. Sci Rep. 2024;14(1):5632.","DOI":"10.1038\/s41598-024-55311-2"},{"key":"10070_CR30","doi-asserted-by":"crossref","unstructured":"Yang L, Zhang Y, Shen C, et al. Publisher correction: clinical features and risk factors of plastic bronchitis caused by Mycoplasma pneumoniae pneumonia in children [J]. BMC Pulm Med. 2023;23(1):499.","DOI":"10.1186\/s12890-023-02800-1"},{"issue":"4","key":"10070_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ppul.22752","volume":"49","author":"Z Luo","year":"2014","unstructured":"Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children [J]. Pediatr Pulmonol. 2014;49(4):377\u201380.","journal-title":"Pediatr Pulmonol"},{"key":"10070_CR32","doi-asserted-by":"publisher","first-page":"1135228","DOI":"10.3389\/fcimb.2023.1135228","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu J, He R, Zhang X, et al. Clinical features and early corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia [J]. Front Cell Infect Microbiol. 2023;13:1135228.","journal-title":"Front Cell Infect Microbiol"},{"key":"10070_CR33","doi-asserted-by":"crossref","unstructured":"Kim Y J Baee, Kang H M, et al. Macrolide versus non-macrolide in combination with steroids for the treatment of Lobar or Segmental Mycoplasma pneumoniae Pneumonia unresponsive to initial macrolide monotherapy [J]. Antibiotics (Basel, Switzerland), 2022, 11(9).","DOI":"10.3390\/antibiotics11091233"},{"issue":"3","key":"10070_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/crj.13584","volume":"17","author":"L Chen","year":"2023","unstructured":"Chen L, Yin J, Liu X, et al. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children [J]. Clin Respir J. 2023;17(3):187\u201396.","journal-title":"Clin Respir J"},{"key":"10070_CR35","doi-asserted-by":"crossref","unstructured":"Fu Y, Zhang T Q, Dong C J, et al. Clinical characteristics of 14 pediatric mycoplasma pneumoniae pneumonia associated thrombosis: a retrospective study [J]. BMC Cardiovasc Disord. 2023;23(1):1.","DOI":"10.1186\/s12872-022-03030-9"},{"issue":"6","key":"10070_CR36","first-page":"5025","volume":"16","author":"X Jin","year":"2018","unstructured":"Jin X, Zhu Y, Zhang Y, et al. Assessment of levels of D-dimer and interferon-\u03b3 in pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication [J]. Experimental Therapeutic Med. 2018;16(6):5025\u201330.","journal-title":"Experimental Therapeutic Med"},{"key":"10070_CR37","doi-asserted-by":"crossref","unstructured":"Grossman E R, Walchek A. Tetracyclines and permanent teeth: the relation between dose and tooth color [J]. Pediatrics. 1971;47(3):567\u201370.","DOI":"10.1542\/peds.47.3.567"},{"issue":"3","key":"10070_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bjid.2013.09.004","volume":"18","author":"H Komatsu","year":"2014","unstructured":"Komatsu H, Tsunoda T, Inui A, et al. Characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumoniae [J]. Brazilian J Infect Diseases: Official Publication Brazilian Soc Infect Dis. 2014;18(3):294\u20139.","journal-title":"Brazilian J Infect Diseases: Official Publication Brazilian Soc Infect Dis"},{"issue":"1","key":"10070_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jiac.2020.08.006","volume":"27","author":"N Kawakami","year":"2021","unstructured":"Kawakami N, Namkoong H, Saito F, et al. Epidemiology of macrolide-resistant Mycoplasma pneumoniae by age distribution in Japan [J]. J Infect Chemotherapy: Official J Japan Soc Chemother. 2021;27(1):45\u20138.","journal-title":"J Infect Chemotherapy: Official J Japan Soc Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10070-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:02:49Z","timestamp":1729090969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10070"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10070-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Following the \u2018Measures for the Ethical Review of Biomedical Research Involving Human Subjects\u2019 of China, this retrospective study was granted ethical approval (Approval Number: K-W-2024-010) by the Institutional Review Board of the Ethics Committee at Tongji Hospital, affiliated with Tongji University in Shanghai. For research using human data with identifiable information, when the subject cannot be located and the research project does not involve personal privacy or commercial interests, the committee waived informed consent. Nevertheless, since the new-generation tetracyclines are available over the counter for children under the age of eight, it is imperative that their legal guardians be informed about the treatment and sign an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1166"}}